GlassScriptPhysician profile
Michael Seward Hall
NPI 1528053972
$801.75
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $161 · 2021: $293 · 2022: $15.33 · 2024: $34.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $209.98 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.25 | 2021 | |
| Abbvie INC. | $109.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $84.99 | 2019-2024 | |
| Abbott Laboratories | $53.13 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $47.70 | 2019-2020 | |
| Allergan, INC. | $39.19 | 2019-2020 | |
| Ibsa Pharma INC. | $29.23 | 2019 | |
| Merck Sharp & Dohme LLC | $27.15 | 2019 | |
| Lilly USA, LLC | $25.55 | 2020 | |
| Pfizer INC. | $24.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.